title: Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
authors.forename: Alain J
authors.initials: AJ
authors.lastname: Gelibter
authors.forename: Sara
authors.initials: S
authors.lastname: Lonardi
authors.forename: Susanna
authors.initials: S
authors.lastname: Di Segni
authors.forename: Andrea
authors.initials: A
authors.lastname: Fontana
authors.forename: Fotios
authors.initials: F
authors.lastname: Loupakis
authors.forename: Francesco
authors.initials: F
authors.lastname: Cognetti
authors.forename: Roberto
authors.initials: R
authors.lastname: Labianca
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D000069287:Capecitabine; D002986:Clinical Trials as Topic / Q000379:methods*; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil / Q000031:analogs & derivatives; D041981:Gastrointestinal Tract / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D012107:Research Design
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003841:Deoxycytidine; D000069287:Capecitabine; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil